Resource utilization and costs among patients with heart failure with reduced ejection fraction following a worsening heart failure event

Michael M. Givertz¹*, Mei Yang², Gregory P. Hess³, Bin Zhao², Ashwin Rai⁴ and Javed Butler⁵

¹Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA, USA; ²Merck & Co., Inc., Kenilworth, NJ, USA; ³Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA; ⁴PRA Health Sciences, Kansas City, MO, USA; ⁵Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA

Abstract

Aims The aim of this study is to characterize healthcare resource utilization and costs in patients with heart failure with reduced ejection fraction (HFrEF) following a worsening heart failure event.

Methods and results This was a retrospective observational cohort analysis. Patients with HFrEF were identified from the PINNACLE Registry and linked to a nationwide pharmacy and medical claims database. Worsening heart failure was defined as stable heart failure with a subsequent hospitalization and/or intravenous diuretic therapy. Healthcare resource use and costs in 2015 US dollars were analysed for dispensed prescriptions, outpatient encounters, and hospital encounters. Among 11 064 patients with HFrEF, 3087 (27.9%) experienced a worsening heart failure event during an average follow-up of 973 days. During the first 30 days after the worsening event, 19.8% of patients had hospital readmissions with heart failure as the primary or secondary diagnosis. During that same time period, mean per patient heart failure-related healthcare resource use included 1.3 prescriptions, 0.5 practitioner visits, and 0.5 hospital encounters (admissions, observations, or emergency care), for an average total medical cost of $8779 per patient including $5359 in heart failure-related costs. During the first year following worsening heart failure onset, mean per patient total and heart failure-related costs were $62 615 and $35 329, respectively.

Conclusions The economic burden following a worsening heart failure event calls for further review of methods to prevent progressive disease, improve adherence to guideline-directed therapy, and develop novel treatments and care strategies to moderate further progression.

Keywords Heart failure/complications; Cost and cost analysis/economics; Health resources; Hospitalization

Introduction

Heart failure-related resource utilization and costs are significant contributors to the national healthcare burden, and heart failure remains one of the most costly chronic diseases.¹ In the United States, approximately 900 000 hospitalizations occur annually for heart failure,² and patients older than 65 years are at particularly high risk for heart failure-related hospitalizations and death.³ Approximately 50% of patients hospitalized for heart failure are readmitted within 6 months of discharge, and almost 30% die within a year.⁴,⁵ It has been estimated that direct costs associated with heart failure in the United States will increase to almost $70 billion by 2030.¹ Estimated indirect costs including lost work and home productivity due to heart failure-related morbidity and premature mortality are estimated at $9.8 billion.¹

Inpatient costs are often the largest component of total medical costs. In the United States, hospitalizations account for 68% of total heart failure healthcare costs.¹ Multiple studies have found that inpatient costs increase with worsening disease severity and comorbid conditions.⁶–⁰ Hospital
readmissions following the initial heart failure diagnosis also contribute to inpatient costs. Within 30 days of hospital discharge, up to 25% of patients are readmitted, while readmission rates increase to 65% at 1 year after discharge.\textsuperscript{5,9,11–15}

Approximately half of patients with heart failure have reduced ejection fraction.\textsuperscript{16} Substantial evidence suggests that worsening heart failure with reduced ejection fraction (HFrEF), characterized by development of progressively escalating symptoms and signs of heart failure requiring intravenous diuretic treatment in the outpatient, emergency department, or hospitalized setting, is associated with markedly worse prognosis.\textsuperscript{17–20} Outcomes for patients with worsening heart failure are poor, and the survival rate at 5 years is less than 50%.\textsuperscript{21} Patients with HFrEF and worsening heart failure also regularly take multiple medications; however, a high percentage of these patients do not receive guideline-recommended regimens.\textsuperscript{22,23}

Few studies assessing heart failure resource utilization and costs have focused on the subset of patients following a worsening heart failure event. From these, we know that about half of hospitalizations among patients with HFrEF are for worsening HF\textsuperscript{13} and about half of these patients are rehospitalized within 30 days of the worsening event.\textsuperscript{22} The objective of this retrospective, observational cohort analysis of registry and claims-based data was to further quantify resource utilization and costs in the subset of patients with HFrEF following a worsening heart failure event.

### Methods

Patients diagnosed with HFrEF between January 1, 2011 and December 31, 2014 (the index period) were identified from the National Cardiovascular Data Registry’s PINNACLE Registry\textsuperscript{8}, the American College of Cardiology’s national, electronic medical record-based outpatient registry capturing data on coronary artery disease, hypertension, heart failure, and atrial fibrillation. Approximately 2500 participating facilities submit data on ambulatory/outpatient care to the PINNACLE Registry. All information comes from data collection forms with International Classification of Diseases 9th and 10th edition codes used to confirm the diagnosis of heart failure. The study design is shown in Figure 1.

The PINNACLE Registry and a nationwide claims database were linked at the patient level using unique patient identifiers. The overlap between the PINNACLE Registry population and the claims [private practitioner claims database (CMS1500), hospital/facility claims database (UB04), and National Council for Prescription Drug Programs claims database] master patient population during the study period was 91%. The integrated data utilized in the study were HIPAA certified. Patients were located across all geographical census regions in the United States and had coverage through commercial, Medicare, Medicaid, and other insurers. The American College of Cardiology and analytics group FIGmd (Rockford, IL) evaluate the mapping criteria and search terms used to populate the registry data fields on an ongoing basis.
basis. Independently, quality assurance and validation were also conducted on the claims data subsets.

**Patient population**

Patients aged $\geq 18$ years with heart failure (defined as having one diagnosis in the index period) and documented ejection fraction of $\leq 45\%$ as a continuous or $< 50\%$ as a categorical value were included in the analysis. The PINNACLE Registry collection form allows for one assessment of ejection fraction. All patients had one or more observed pharmacy and medical claims within 180 days prior to the heart failure diagnosis date and $\geq 365$ days after the diagnosis date or a record of mortality. Patients were excluded if they had evidence of clinical trial participation or heart transplantation between January 1, 2011 and December 31, 2014, or left ventricular assist device implantation, adult congenital heart disease, or amyloidosis during the 180 days prior to the heart failure diagnosis.

**Worsening heart failure event**

Within the cohort of patients with HFrEF, a subcohort of patients with a worsening heart failure event was identified through June 30, 2016 (Figure 1). This subcohort was defined as patients who had $\geq 30$ days of initial heart failure therapy after their HFrEF diagnosis was identified from the pharmacy database, were stabilized for $\geq 90$ days from the date of HFrEF diagnosis (defined as being free from heart failure-related emergency care, hospitalizations, and outpatient intravenous diuretic administrations), and after demonstration of stabilization, subsequently required at least one intravenous diuretic treatment in any healthcare setting (identified from the pharmacy claims database) or had a heart failure-related hospitalization (primary or secondary diagnosis from hospital/facility claims database). Similar definitions of worsening heart failure have been used in previously published studies.\(^{18,24}\)

**Study measures and analyses**

The study objectives were to characterize healthcare resource utilization, costs, and risks for hospitalization over the 24 months following the initial worsening heart failure event in the subcohort of patients with HFrEF. Diagnostic, therapeutic, and procedural information was assessed using data from the PINNACLE Registry, private practitioner claims database (CMS1500), and hospital/facility claims database (UB04) including inpatient stays and observation visits, as well as emergency department care. Data on treatment included National Council for Prescription Drug Programs claims for dispensed medication from pharmacies contributing to the patient data repository.

Descriptive analyses were used for baseline patient characteristics. Categorical variables were summarized as the number and corresponding percentages of patients. Continuous variables were presented as the mean and standard deviation (SD). Healthcare resource utilization was evaluated from the worsening event through the subsequent 24 months and presented as per person per month utilization in terms of outpatient-dispensed prescriptions, outpatient encounters (e.g., physician office and clinic), and hospital encounters (including admissions, observational visits, and emergency department care). The dispensed medication costs reflect the amounts paid by insurers, and medical costs represent the amount charged to insurers. Costs were from the pre-adjudicated claims submitted to payers, and both costs were adjusted to 2015 US dollars using the Consumer Price Index. Population level data included all healthcare resource utilization and costs, and all patients contributed to the denominator totals whether or not they contributed to the numerator. Both total (all-cause) and heart failure-related (based on primary or secondary diagnosis) resource use and costs were examined for the first 30 days (1 month) and then at 3 month intervals up to the first 24 months after the worsening heart failure event. Costs were presented as cumulative costs. Mortality was not an endpoint of this study, but death was used to define ‘alive and observable’. Mortality was determined directly from the PINNACLE Registry or medical/hospital claims based on International Classification of Diseases 9th and 10th edition codes, procedures codes, or discharge status (if available).

**Ethics statement**

The investigation conforms with the principles outlined in the Declaration of Helsinki.

**Results**

Among the 11,064 patients with HFrEF that met the selection criteria, 3087 (27.9\%) had a worsening heart failure event during an average follow-up of 973 days. The mean (SD) time from heart failure diagnosis to the initial worsening heart failure event was $1.3 (0.9)$ years.

**Patient characteristics**

Baseline demographic characteristics are shown in Table 1. Mean patient age was 71 years, and 72\% of patients were $\geq 65$ years of age. The majority were male patients (65\%), and 63\% of patients were Caucasian. The largest proportion
of patients (41%) were from the Southern region, and slightly more than half of patients (56%) were Medicare recipients.

Clinical characteristics in the 6 months prior to the worsening heart failure event are shown in Table 2. Among patients with available data, the largest proportion were in New York Heart Association functional class II (23%) or III (14%), and slightly more patients had moderately (34%) or severely (36%) reduced ejection fraction (defined as ejection fractions between 30–39% and <30%, respectively) than mildly (30%) reduced ejection fraction (defined as ejection fraction between 40% and 45%). Body mass indices were above normal (overweight [22%] or obese [30%]) for the majority of patients.

Comorbidities

All patients had at least one cardiac or non-cardiac comorbidity (data not shown). The majority of patients had hypertension (93%), coronary artery disease (79%), abnormal lipid profiles (78%), atrial fibrillation (57%), diabetes mellitus (54%), and myocardial infarction (52%). A smaller proportion of patients had anaemia (43%), chronic obstructive pulmonary disease (42%), chronic kidney disease (29%), peripheral artery disease (33%), sleep apnoea (25%), depression (17%), thromboembolism (10%), or stroke (11%). Patient history of procedures included implantable cardioverter defibrillator (28%), coronary artery bypass graft (19%), biventricular pacemaker (10%), and cardiac valve surgeries (2%).

Treatment

Initial therapy reported at the time of the worsening heart failure event included monotherapy or two-class combination therapy (35% and 47% of patients, respectively), with a smaller percentage receiving three-class combination therapy (18%; data not shown). Monotherapy was predominantly beta blockers while two-class combination therapy was predominantly beta blockers plus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers. Three-class combination therapy was predominantly beta blockers plus mineralocorticoid receptor antagonists plus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers.

Healthcare resource utilization

Total and heart failure-related resource utilization for the number of prescriptions, outpatient encounters, and hospital encounters during the first 30 days and at 3 month intervals through 24 months after the worsening heart failure event is shown in Figure 2A–C. Total utilization per patient

| Characteristic | Patients (N = 3087) |
|---------------|---------------------|
| Age (years), mean (SD) | 70.9 (12.5) |
| Age (years) distribution | |
| 18-44 | 98 (3.2) |
| 45-54 | 232 (7.5) |
| 55-64 | 542 (17.6) |
| 65-74 | 864 (28.0) |
| 75-79 | 451 (14.6) |
| ≥80 | 900 (29.2) |
| Sex | |
| Male | 1993 (64.6) |
| Race | |
| Caucasian | 662 (62.8) |
| African American | 367 (11.9) |
| Other | 38 (1.2) |
| Unknown | 744 (24.1) |
| Geographic region | |
| South | 1275 (41.3) |
| Midwest | 831 (26.9) |
| West | 598 (19.4) |
| Northeast | 383 (12.4) |
| Payer type | |
| Medicare | 1715 (55.6) |
| Commercial | 598 (19.4) |
| None | 49 (1.6) |
| Medicaid | 38 (1.2) |
| Other | 7 (0.2) |
| Unknown | 680 (22.0) |

SD, standard deviation.
Data presented as n (%) unless indicated otherwise.

| Characteristic | Patients (N = 3087) |
|---------------|---------------------|
| New York Heart Association functional class | |
| Class I | 299 (9.7) |
| Class II | 701 (22.7) |
| Class III | 438 (14.2) |
| Class IV | 51 (1.7) |
| Unknown | 1598 (51.8) |
| Left ventricular ejection fraction, mean (SD) | |
| Mildly reduced (40–45) | 31.5 (9.7) |
| Moderately reduced (30–39) | 393 (30.3) |
| Severely reduced (<30) | 1047 (33.9) |
| Systolic blood pressure, mean (SD) mmHg | |
| <120 | 120.2 (19.5) |
| 120–130 | 69.2 (11.6) |
| 130–140 | 75.1 (14.9) |
| 140–150 | 1.6 (1.4) |
| Body mass index | |
| Underweight (<18.5) | 47 (1.5) |
| Normal (18.5–24.9) | 505 (16.4) |
| Overweight (25.0–29.9) | 688 (22.3) |
| Obese (≥30.0) | 920 (29.8) |
| Unknown | 927 (30.0) |

SD, standard deviation.
Data presented as n (%) unless indicated otherwise.
Available for a subset of the population (n = 2152 for systolic blood pressure, n = 2148 for diastolic blood pressure, n = 2040 for heart rate, and n = 496 for serum creatine).

| Characteristic | Patients (N = 3087) |
|---------------|---------------------|
| Serum creatinine, mean (SD) mg/dL | |
| 1.6–2.5 | 1.6 (1.4) |
| 2.6–3.0 | 1.6 (1.4) |
| 3.1–3.5 | 1.6 (1.4) |
| 3.6–4.0 | 1.6 (1.4) |
| 4.1–5.0 | 1.6 (1.4) |
| 5.1–7.0 | 1.6 (1.4) |

SD, standard deviation.
Data presented as n (%) unless indicated otherwise.

Available for a subset of the population (n = 2152 for systolic blood pressure, n = 2148 for diastolic blood pressure, n = 2040 for heart rate, and n = 496 for serum creatine).
per month for all utilization was highest in the first 30 days following the worsening event and then gradually decreased over the next 9–12 months with little or no fluctuation through 24 months.

A similar trend was observed for heart failure-related resource utilization. Specifically, the mean number of heart failure-related prescriptions was 1.3 prescriptions per patient per month during the first 30 days after the initial worsening event and then slightly decreased, with the mean number of prescriptions ranging from 1.0 to 1.2 (Figure 2A). Outpatient heart failure-related medical visits were also highest during the first 30 days (0.5 visits per patient per month), and then decreased to 0.2 visits per patient per month after 9 months of follow-up (Figure 2B). Similarly, there were 0.5 heart failure-related hospital encounters per patient per month during the first 30 days, decreasing to 0.1 hospital encounters per patient per month over 24 months (Figure 2C).

The percentage of patients with all-cause hospital admissions (inpatient stays) ranged from 31.6% in the first 30 days to 75.5% over the first 24 months (data not shown). A similar trend was observed in the heart failure-related hospital admissions. In the first 30 days, 3, 12, and 24 months from the incident worsening event, 19.8%, 32.1%, 47.4%, and 60.2% of patients had a heart failure-related admission, respectively (data not shown).

**Healthcare costs**

Costs for prescriptions, outpatient encounters, and hospital encounters during the 30 days following the worsening heart failure event through 24 months are shown in Supporting Information, Table S1 and Figure 3. During the first 30 days, total mean (SD) per patient costs were $8779 (±33 720) for all-cause prescriptions, outpatient encounters, and inpatient care and $5359 (±29 274) for heart failure-related prescriptions, outpatient encounters, and inpatient care. During the first year following the worsening heart failure event, the mean (SD) per-patient cost for total care was $62 615 (±132 771) and the mean cost of heart failure-related care was $38 329 (±105 657). Over the 24 months after the worsening event, mean (SD) per-patient costs were $131 967 (±235 359) and $72 947 (±170 823) for total and heart failure-related resource use, respectively. Costs for heart failure-related prescriptions and outpatient visits accounted for 35% and 33% of total costs in those categories, while the cost of heart failure-related hospital encounters accounted for 64% of the all-cause hospital encounters cost.

In general, total heart failure-related costs were driven primarily by heart failure-related hospital encounters, which represented 94% of total costs in the first 30 days following the worsening heart failure event and were maintained at a high level through 24 months. On the other hand, outpatient heart failure-related drug costs only accounted for approximately 2–3% of the total heart failure-related costs and 1% of the total costs from the first 30 days through 24 months of follow-up (Table S1).

Cost data were further stratified by patient characteristics, including geographical region, age, race, and sex. Mean costs within 24 months, stratified by regions of the United States, were lowest for patients in the South ($123 247), highest in the Northeast ($146 110) and similar in the Midwest and West ($133 051 and $132 455, respectively; data not shown). Costs stratified by patient age were highest for younger patients aged 18–44 years ($259 090) and decreased with increasing age over 24 months (Figure S1A).
Furthermore, costs over 24 months for patients age 80 years and older were 28–65% of those in the other age groups. Stratification by race showed that over 24 months, utilization costs were 1.4 times higher for African American patients than Caucasian patients (Figure S1B). Costs were similar between sex with the percent difference in female and male participants never exceeding 10% through the 24 month time point (Figure S1C).

**Discussion**

This study provides real-world data on resource utilization and healthcare costs among a cohort of patients with HFrEF following a worsening heart failure event. To our knowledge, this is the first study of patients in a real-world setting that specifically examines resource utilization and costs following a worsening event. A worsening event, characterized by escalating symptoms and signs of congestion requiring intravenous diuretics, is associated with markedly worse prognosis and 5 year survival rates of <50%. In the present study, 28% of patients with HFrEF experienced a worsening event within 24 months of heart failure diagnosis. As we recently showed in the worsening HF population, the use of guideline-recommended therapy is concerning. The extent of economic burden from direct medical costs is substantial in this population and derives primarily from inpatient care.

By focusing on the subset of patients experiencing a worsening heart failure event, our study adds to data published from National Claims History files from the Centers for Medicare and Medicaid Services, the National Inpatient Sample collected by the Agency for Healthcare Research and Quality, and Olmsted County, Minnesota. While other studies have identified characteristics and outcomes for patients with chronic HFrEF, the subset of patients that develop worsening heart failure has emerged as a distinct group, and investigating these individuals presents opportunities to improve outcomes and reduce costs.

In the present study, 20% of patients who experienced a worsening heart failure event had heart failure-related hospital readmissions within 30 days after the worsening event, and 32% had readmissions for any reason. These results are substantially higher than readmission rates reported for all patients (i.e. excluding the subset of patients with a worsening event) after a primary diagnosis of heart failure. Among Medicare beneficiaries, all-cause readmissions within 30 days of heart failure diagnosis were 22–23%. Similar to these studies of the overall population, mean per person direct healthcare costs per year were $23 854 (2014 US dollars), with inpatient costs representing the most significant contribution (47% of total costs, $11 318). In addition, results from a retrospective study of Medicare patients aged ≥65 years with heart failure reported total annual costs per person of $22 230 (2009 US dollars). Similar to these studies of the overall population of patients with HFrEF, our analysis of patients following a...
worsening heart failure event also identifies inpatient encounters as the major contributor to overall costs. Furthermore, the results for total and heart failure-related costs following the worsening heart failure event reported here are similar to those previously reported by Obi et al.\textsuperscript{32} for a cohort of patients with heart failure that died within 1 year after the initial heart failure encounter. Decedents incurred $60,048 (2013 US dollars) in total all-cause costs and $39,052 (2013 US dollars) in heart failure-related medical costs in 1 year, which was two to three times the costs incurred by a matched cohort of patients that survived 1 year ($32,394 and $16,519, respectively, both $0 < 0.001).\textsuperscript{32}

In a cohort of patients with worsening heart failure similar to those followed in the present study, there was a rapid decline in survival beginning shortly after the worsening event, and ~30% of these patients were not alive within 1 year.\textsuperscript{22} Most of these patients did not receive recommended heart failure therapy or doses prior to developing worsening heart failure.\textsuperscript{22,32} Previously published data highlight this unmet need to address factors that may improve outcomes for patients after a worsening heart failure event. Addressing these factors would also help reduce the high associated direct medical costs and healthcare utilization identified in the present analysis.

This study is subject to the limitations of registry and claims data. The costs in this study are charges from the pre-adjudicated claims submitted to payers, and not the costs reimbursed by payers. Using charges can lead to an overestimation of costs, which could partially explain why costs reported in the present study were higher than in previously reported studies. In addition, it is possible that random missing data can bias results; however, we would not expect this to alter the principal findings and conclusions of the present study. To strengthen the present study, we linked registry and claims databases in order to access both clinical and pharmacy data for the population of patients with HFrEF that would not be available in claims databases alone where some patients are recorded with unspecified heart failure based on International Classification of Diseases 9th and/or 10th edition codes. The study design incorporated a single evaluation of ejection fraction, which is a potential drawback, because the ejection fraction of patients included in the analysis may have normalized over time. However, we focused on the population of patients with an ejection fraction ≤45% to capture patients with midrange reduced ejection fraction, and several clinical trials over the last two decades have used an ejection fraction cut-off of 45%.\textsuperscript{20,33}

In summary, more than one in four patients with HFrEF will develop worsening heart failure and are at high risk for 30 days of rehospitalization and additional healthcare resource utilization. The extent of economic burden following the development of worsening heart failure calls for further review of interventions to prevent progressive disease and development of novel treatments to moderate further progression once heart failure has worsened. Further studies are needed to better understand the economic burden following the development of worsening heart failure in different countries. The resource utilization and costs reported here provide a benchmark against which to measure the results of future improvements in the care of patients with worsening heart failure.

Acknowledgements

Patrice C. Ferriola, PhD (KZE PharmAssociates, LLC), helped in preparation and editing of the manuscript. This research uses data from the ACC’s National Cardiovascular Data Registry. The views expressed in this manuscript represent those of the author(s), and do not necessarily represent the official views of the NCDR or its associated professional societies identified at CVQuality.ACC.org/NCDR.

Conflict of interest

M. Givertz has research support from the National Institutes of Health and serves as a consultant to Merck. J. Butler has received research support from the National Institutes of Health, PCORI, and the European Union and serves as a consultant for Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squib, CVRx, G3 Pharmaceutical, Innolife, Janssen, Luitpold, Medtronic, Merck, Novartis, Relypsa, StealthPeptide, SC Pharma, Vifor, and ZS Pharma. G. Hess was previously employed by Symphony Health, which received research support from Merck & Co. for the design and conduct of this study. G. Hess also conducts funded studies with governmental agencies, for example, the NIH, and professional societies, for example, the American College of Cardiology. M. Yang and B. Zhao are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., and are shareholders of Merck & Co., Inc., Kenilworth, NJ, USA.

Funding

Support for this study was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.
Table S1. Mean healthcare costs and heart failure-related costs per-patient following a worsening heart failure event.

Figure S1. Total mean adjusted costs following a worsening heart failure event by (A) age, (B) race, and (C) sex.

References

1. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khajyoub O, Konstam MA, Maddox TM, Nichol G, Pham M, Pina IL, Trogdon JG. American Heart Association Advocacy Coordinating Committee, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. *Circ Heart Fail* 2013; 6: 606–619.

2. Hall MJ, Levant S, DeFrances CJ. Hospitalization for congestive heart failure: United States, 2000–2010. *NCHS Data Brief* 2012; 1–8.

3. Liao L, Allen LA, Whellan DJ. Economic burden of heart failure in the elderly. *Pharmacoconomics* 2008; 26: 447–462.

4. Setoguchi S, Stevenson LW. Hospitalizations in patients with heart failure: who and why. *J Am Coll Cardiol* 2009; 54: 1703–1705.

5. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. *Am Heart J* 2007; 154: 260–266.

6. Kociol RD, Liang L, Hernandez AF, Curtis LH, Heidenreich PA, Yancy CW, Fonarow GC. Are we targeting the right metric for heart failure? Comparison of hospital 30-day readmission rates and total episode of care inpatient days. *Am Heart J* 2013; 165: 987–994.e1.

7. Mejhert M, Lindgren P, Schill O, Edner MA, Maddox TM, Nichol G, Pham M, Pina IL, Trogdon JG. American Heart Association Advocacy Coordinating Committee, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Stroke Council. Hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. *J Am Coll Cardiol* 2014; 63: 1123–1133.

8. Okumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJ, PARADIGM-HF Investigators and Committees*. Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). *Circulation* 2016; 133: 2254–2262.

9. Skali H, Dwyer EM, Goldstein R, Haigney M, Krone R, Kukin M, Lichtenstein E, McNitt S, Moss AJ, Pfeffer MA, Solomon SD. Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT. *Eur J Heart Fail* 2014; 16: 560–565.

10. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM, Group VS. Vericiguat in patients with heart failure and reduced ejection fraction. *N Engl J Med* 2020; 382: 1883–1893.

11. Koudstaal S, Pujades-Rodriguez M, Denaxas S, Gho J, Shah AD, Yu N, Patel RS, Gale CP, Hoes AW, Cleland JG, Asselbergs FW, Hemingway H. Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people. *Eur J Heart Fail* 2017; 19: 1119–1127.

12. Butler J, Yang M, Manzi MA, Hess GP, Patel MJ, Rhodes T, Givertz MM. Clinical course of patients with worsening heart failure with reduced ejection fraction. *J Am Coll Cardiol* 2019; 73: 935–944.

13. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Jhund PS, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *J Card Fail* 2017; 23: 628–651.

The Guidelines. *J Card Fail* 2011; 17: 649–656.

11. Santas E, Valero E, Mollan A, Garcia-Blas S, Palau P, Minana G, Nunez E, Sanchis J, Chorro FJ, Nunez J. Burden of recurrent hospitalizations following an admission for acute heart failure: preserved versus reduced ejection fraction. *Rev Esp Cardiol (Engl Ed)* 2017; 70: 239–246.

12. Swindle JP, Chan WW, Walman Johnson K, Becker L, Blauer-Peterson C, Altan A. Evaluation of mortality and readmissions following hospitalization with heart failure. *Curr Med Res Opin* 2016; 32: 1745–1755.

13. Bress AP, King JB, Brixner D, Kielhorn A, Patel HK, Maya J, Lee VC, Biskupiak J, Munger M. Pharmacotherapy treatment patterns, outcomes, and health resource utilization among patients with heart failure with reduced ejection fraction at a U.S. academic medical center. *Pharmacotherapy* 2016; 36: 174–186.

14. Kilgore M, Patel HK, Kielhorn A, Maya JF, Sharma P. Economic burden of hospitalizations of Medicare beneficiaries with heart failure. *Risk Manag Healthc Policy* 2017; 10: 63–70.

15. Ross JS, Chen J, Lin Z, Bueno H, Curtis JP, Keenan PS, Normand SL, Schreiner G, Sperrus JA, Vidan MT, Wang Y, Wang Y, Krumholz HM. Recent national trends in readmission rates after heart failure hospitalization. *Circ Heart Fail* 2010; 3: 97–103.

16. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mustillo ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. *Circulation* 2020; 141: e139–e596.

17. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CSP, Sato N, Shah AN, Gheorghiade M. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. *J Am Coll Cardiol* 2014; 63: 1123–1133.

18. Okumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJ, PARADIGM-HF Investigators and Committees*. Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). *Circulation* 2016; 133: 2254–2262.

19. Skali H, Dwyer EM, Goldstein R, Haigney M, Krone R, Kukin M, Lichtenstein E, McNitt S, Moss AJ, Pfeffer MA, Solomon SD. Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT. *Eur J Heart Fail* 2014; 16: 560–565.

20. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM, Group VS. Vericiguat in patients with heart failure and reduced ejection fraction. *N Engl J Med* 2020; 382: 1883–1893.

21. Koudstaal S, Pujades-Rodriguez M, Denaxas S, Gho J, Shah AD, Yu N, Patel RS, Gale CP, Hoes AW, Cleland JG, Asselbergs FW, Hemingway H. Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people. *Eur J Heart Fail* 2017; 19: 1119–1127.

22. Butler J, Yang M, Manzi MA, Hess GP, Patel MJ, Rhodes T, Givertz MM. Clinical course of patients with worsening heart failure with reduced ejection fraction. *J Am Coll Cardiol* 2019; 73: 935–944.

23. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *J Card Fail* 2017; 23: 628–651.
24. Butler J, Braunwald E, Gheorghiade M. Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. *JAMA* 2014; 312: 789–790.

25. Chen J, Dharmarajan K, Wang Y, Krumholz HM. National trends in heart failure hospital stay rates, 2001 to 2009. *J Am Coll Cardiol* 2013; 61: 1078–1088.

26. Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. *JAMA* 2011; 306: 1669–1678.

27. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, Killian JM, Roger VL. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. *JAMA Intern Med* 2015; 175: 996–1004.

28. Echouffo-Tcheugui JB, Bishu KG, Fonarow GC, Egede LE. Trends in healthcare expenditure among US adults with heart failure: the Medical Expenditure Panel Survey 2002-2011. *Am Heart J* 2017; 186: 63–72.

29. Fitch K, Pelizzari PM, Pyenson B. Inpatient utilization and costs for Medicare fee-for-service beneficiaries with heart failure. *Am Health Drug Benefits* 2016; 9: 96–104.

30. Greene SJ, Mentz RJ, Felker GM. Outpatient worsening heart failure as a target for therapy: a review. *JAMA Cardiol* 2018; 3: 252–259.

31. Bogner HR, Miller SD, de Vries HF, Chhatre S, Jayadevappa R. Assessment of cost and health resource utilization for elderly patients with heart failure and diabetes mellitus. *J Card Fail* 2010; 16: 454–460.

32. Obi EN, Swindle JP, Turner SJ, Russo PA, Altan A. Healthcare costs among patients with heart failure: a comparison of costs between matched decedent and survivor cohorts. *Adv Ther* 2017; 34: 261–276.

33. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. *N Engl J Med* 1997; 336: 525–533.